Meeting
2018 ASCO Annual Meeting
Effect of rilimogene galvacirepvec/rilimogene glafolivec on intra/peritumoral immune infiltrate in patients with localized prostate cancer undergoing radical prostatectomy.
Authors
James L. Gulley
Genitourinary Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD
James L. Gulley , Houssein Abdul Sater , Jenn Marte , Renee Nicole Donahue , Beatriz Walter Rodriguez , Christopher Ryan Heery , Mark Stern , Debrah Thompson , Lisa M. Cordes , Guinevere Chun , Fatima Karzai , Marijo Bilusic , Jeffrey Schlom , William L. Dahut , Ravi Amrit Madan , Peter A. Pinto
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Prostate) Cancer
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer–Local-Regional Disease
Clinical Trial Registration Number
NCT02153918
Citation
J Clin Oncol 36, 2018 (suppl; abstr 5083)
DOI
10.1200/JCO.2018.36.15_suppl.5083
Abstract #
5083
Poster Bd #
310
Abstract Disclosures
Similar Posters
Poster
2019 Genitourinary Cancers Symposium
Immune infiltrate with CD8 low or PDL1 high associated with metastatic prostate cancer after radical prostatectomy (RP).
First Author: Cecile Vicier
Poster
2023 ASCO Genitourinary Cancers Symposium
Effect of neoadjuvant stereotactic body radiation therapy (SBRT) on the immune microenvironment of high-risk localized prostate cancer in paired transcriptomic analysis of pretreatment biopsy and irradiated prostatectomy specimens.
First Author: Ariel E. E. Marciscano
Poster
2023 ASCO Genitourinary Cancers Symposium
A randomized phase II trial of neoadjuvant chemokine modulation in patients with localized prostate cancer undergoing radical prostatectomy.
First Author: Karan Jatwani